The Laboratory Diagnosis of Hepatitis B Virus
Hepatitis B virus (HBV) chronically infects approximately 250,000 Canadians and 350 million people worldwide. Without intervention, approximately 15% to 40% of chronically infected individuals will eventually develop cirrhosis, end-stage liver disease or hepatocellular carcinoma, or require liver tr...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2005-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2005/450574 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560795028815872 |
|---|---|
| author | Mel Krajden Gail McNabb Martin Petric |
| author_facet | Mel Krajden Gail McNabb Martin Petric |
| author_sort | Mel Krajden |
| collection | DOAJ |
| description | Hepatitis B virus (HBV) chronically infects approximately 250,000 Canadians and 350 million people worldwide. Without intervention, approximately 15% to 40% of chronically infected individuals will eventually develop cirrhosis, end-stage liver disease or hepatocellular carcinoma, or require liver transplantation. The availability and extensive use of the HBV vaccine has dramatically reduced the number of incident infections in Canada and worldwide. Effective therapeutic agents have been and continue to be developed to treat chronic infection. The present review provides a comprehensive overview of diagnostic tests for HBV infection and immunity, and elaborates on HBV risk factors, vaccine prevention and therapeutic monitoring. HBV diagnosis is accomplished by testing for a series of serological markers of HBV and by additional testing to exclude alternative etiological agents such as hepatitis A and C viruses. Serological tests are used to distinguish acute, self-limited infections from chronic HBV infections and to monitor vaccine-induced immunity. Nucleic acid testing for HBV-DNA is increasingly being used to quantify HBV viral load and measure the effectiveness of therapeutic agents. Given the multitude of available tests and the complexity of clinical management, there is a critical need for greater coordination among clinicians, diagnostic laboratory personnel and researchers to define optimal laboratory diagnostic and monitoring assays so that the appropriate tests are used to maximize prevention and optimize treatment outcomes. |
| format | Article |
| id | doaj-art-2b8d4bd6e46d4fa49de90741e6c8f5a8 |
| institution | Kabale University |
| issn | 1712-9532 |
| language | English |
| publishDate | 2005-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-2b8d4bd6e46d4fa49de90741e6c8f5a82025-02-03T01:26:38ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322005-01-01162657210.1155/2005/450574The Laboratory Diagnosis of Hepatitis B VirusMel Krajden0Gail McNabb1Martin Petric2British Columbia Centre for Disease Control, Vancouver, British Columbia, CanadaBritish Columbia Centre for Disease Control, Vancouver, British Columbia, CanadaBritish Columbia Centre for Disease Control, Vancouver, British Columbia, CanadaHepatitis B virus (HBV) chronically infects approximately 250,000 Canadians and 350 million people worldwide. Without intervention, approximately 15% to 40% of chronically infected individuals will eventually develop cirrhosis, end-stage liver disease or hepatocellular carcinoma, or require liver transplantation. The availability and extensive use of the HBV vaccine has dramatically reduced the number of incident infections in Canada and worldwide. Effective therapeutic agents have been and continue to be developed to treat chronic infection. The present review provides a comprehensive overview of diagnostic tests for HBV infection and immunity, and elaborates on HBV risk factors, vaccine prevention and therapeutic monitoring. HBV diagnosis is accomplished by testing for a series of serological markers of HBV and by additional testing to exclude alternative etiological agents such as hepatitis A and C viruses. Serological tests are used to distinguish acute, self-limited infections from chronic HBV infections and to monitor vaccine-induced immunity. Nucleic acid testing for HBV-DNA is increasingly being used to quantify HBV viral load and measure the effectiveness of therapeutic agents. Given the multitude of available tests and the complexity of clinical management, there is a critical need for greater coordination among clinicians, diagnostic laboratory personnel and researchers to define optimal laboratory diagnostic and monitoring assays so that the appropriate tests are used to maximize prevention and optimize treatment outcomes.http://dx.doi.org/10.1155/2005/450574 |
| spellingShingle | Mel Krajden Gail McNabb Martin Petric The Laboratory Diagnosis of Hepatitis B Virus Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | The Laboratory Diagnosis of Hepatitis B Virus |
| title_full | The Laboratory Diagnosis of Hepatitis B Virus |
| title_fullStr | The Laboratory Diagnosis of Hepatitis B Virus |
| title_full_unstemmed | The Laboratory Diagnosis of Hepatitis B Virus |
| title_short | The Laboratory Diagnosis of Hepatitis B Virus |
| title_sort | laboratory diagnosis of hepatitis b virus |
| url | http://dx.doi.org/10.1155/2005/450574 |
| work_keys_str_mv | AT melkrajden thelaboratorydiagnosisofhepatitisbvirus AT gailmcnabb thelaboratorydiagnosisofhepatitisbvirus AT martinpetric thelaboratorydiagnosisofhepatitisbvirus AT melkrajden laboratorydiagnosisofhepatitisbvirus AT gailmcnabb laboratorydiagnosisofhepatitisbvirus AT martinpetric laboratorydiagnosisofhepatitisbvirus |